Alnylam Issues 2023 Corporate Responsibility Report
May 07 2024 - 8:00AM
Business Wire
– Highlighted New Disclosures of Company’s
Impact on the Environment—Including Multiyear Data on Greenhouse
Gas (GHG) Emissions, Energy, Water, and Waste Management
Footprint–
– Expanded Alnylam Challengers Global Health
Equity Initiative –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today the publication of its 2023
Corporate Responsibility Report. The company continues to take
meaningful steps across each of its six corporate responsibility
pillars. This year’s edition expands data disclosures across each
pillar and highlights examples of the company’s commitment to
ensuring patient access, reducing health inequities, and being a
responsible steward of the environment.
“As we grow and progress in our quest to realize the promise of
RNAi, we continue to expand our leadership and impact as a
responsible corporate citizen. I am proud of the broad range of
initiatives highlighted in this report, which reflect our efforts
to continually increase the value that we contribute to society,”
said Yvonne Greenstreet, MBChB, Chief Executive Officer of
Alnylam.
Key highlights from the 2023 report include:
- Published new data on Alnylam’s environmental impact.
Disclosed and third-party verified multiyear data on scope 1, scope
2, and select scope 3 GHG emissions. Published multiyear data on
energy, water and waste management footprint.
- Expanded partnerships and strategies to support diversity
and inclusion within clinical trials. Joined the Novartis-led
Beacon of Hope Initiative, a ten-year collaboration with
Historically Black Colleges and Universities (HBCUs) to address
root causes of health disparities. Activated strategies to reach
underserved communities by developing culturally appropriate
clinical trial materials, training clinical trial staff, and
improving plain language summaries.
- Extended reach of Alnylam Challengers global health equity
initiative. Grew signature social impact program to include 5
countries in which Alnylam has a local presence. Highlighted
programmatic impact of partnerships with innovative social
entrepreneurs and non-profit organizations working on the
frontlines to address health and economic inequalities.
- Shared new employee demographic data and results of pay
equity analysis. Released new employee demographic data and
highlighted results of a recent annual pay equity analysis.
To learn more about corporate responsibility at Alnylam,
download the full 2023 Corporate Responsibility Report here.
About Alnylam Pharmaceuticals Alnylam Pharmaceuticals
(Nasdaq: ALNY) has led the translation of RNA interference (RNAi)
into a whole new class of innovative medicines with the potential
to transform the lives of people afflicted with rare and prevalent
diseases with unmet need. Based on Nobel Prize-winning science,
RNAi therapeutics represent a powerful, clinically validated
approach yielding transformative medicines. Since its founding in
2002, Alnylam has led the RNAi Revolution and continues to deliver
on a bold vision to turn scientific possibility into reality.
Alnylam’s commercial RNAi therapeutic products are ONPATTRO®
(patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO®
(lumasiran), and Leqvio® (inclisiran), which is being developed and
commercialized by Alnylam’s partner, Novartis. Alnylam has a deep
pipeline of investigational medicines, including multiple product
candidates that are in late-stage development. Alnylam is executing
on its “Alnylam P5x25” strategy to deliver transformative medicines
in both rare and common diseases benefiting patients around the
world through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn,
Facebook, or Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507507791/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom (Investors and Media)
+1-617-682-4340
Josh Brodsky (Investors) +1-617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Jul 2023 to Jul 2024